Paratek Pharmaceuticals, Inc.
PRTKNASDAQHealthcare
$2.23
+$0.04(+1.83%)
Market Cap$127828952
P/E Ratio—
52W High$3.65
52W Low$1.29
Paratek Pharmaceuticals, Inc.（PRTK）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · PRTK · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.06B) | ($0.06B) | ($0.10B) | ($0.13B) | ($0.11B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | ($0.00B) | ($0.00B) |
| Stock-Based Comp. | $0.01B | $0.01B | $0.01B | $0.01B | $0.03B |
| Change in Working Capital | ($0.02B) | ($0.01B) | ($0.02B) | ($0.02B) | $0.00B |
| Net Cash from Operations | ($0.07B) | ($0.05B) | ($0.10B) | ($0.13B) | ($0.08B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.02B) | ($0.02B) | ($0.03B) | ($0.10B) | ($0.29B) |
| Sales of Investments | $0.03B | $0.02B | $0.12B | $0.24B | $0.17B |
| Net Cash from Investing | $0.01B | $0.00B | $0.09B | $0.13B | ($0.13B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.01B | $0.02B | $0.01B | $0.06B | $0.22B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.07B) | ($0.05B) | ($0.10B) | ($0.13B) | ($0.08B) |
| FCF Margin %(computed) | -43.89% | -40.22% | -238.53% | -811.68% | -474.61% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Paratek Pharmaceuticals, Inc.
关于Paratek Pharmaceuticals, Inc.（PRTK）现金流量表
Paratek Pharmaceuticals, Inc. 2022财年经营活动现金流($0.07B)，自由现金流($0.07B)（FCF利润率-43.89%），资本支出($0.00B)。
常见问题
PRTK · 4 问Paratek Pharmaceuticals, Inc. 2022财年自由现金流($0.07B)，同比down36.0%。
PRTK free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10